Global Prescription Weight Loss Pills Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Prescription Weight Loss Pills Market Research Report 2024
Health care professionals use the Body Mass Index (BMI), a measure of people weight in relation to height, to define overweight and obesity. People who have a BMI between 25 and 30 are considered to be overweight. Obesity is defined as having a BMI of 30 or greater. Are overweight, obese, or severely obese, which may increase risk of developing health problems. Obesity is a chronic disease and prescription medications to treat overweight and obesity work in different ways. Prescription weight loss medicines can help obese people lose weight. They are usually prescribed by a doctor when diet and exercise alone are not working. Each of these medicines works differently. People who use these medicines may not feel as hungry. Or they may feel full after eating only a small amount of food. Another type of weight-loss medicine makes it harder for your body to absorb fat. Prescription weight loss drugs can be helpful when used in combination with a low-calorie diet and regular physical activity.
According to Mr Accuracy reports new survey, global Prescription Weight Loss Pills market is projected to reach US$ 2625.3 million in 2029, increasing from US$ 1130 million in 2022, with the CAGR of 10.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prescription Weight Loss Pills market research.
Rising conditions such as obesity, cardiovascular diseases, diabetes, and hypertension are increasing the revenue share of the global weight loss drugs market. Moreover, these drugs are used to maintain a healthy body weight amid growing adoption of a healthy lifestyle, thereby driving the expansion of the market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prescription Weight Loss Pills market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)
Segment by Type
Oral Tablets
Oral Capsules
Injections
Hospital
Pharmacy
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prescription Weight Loss Pills report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Prescription Weight Loss Pills market is projected to reach US$ 2625.3 million in 2029, increasing from US$ 1130 million in 2022, with the CAGR of 10.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prescription Weight Loss Pills market research.
Rising conditions such as obesity, cardiovascular diseases, diabetes, and hypertension are increasing the revenue share of the global weight loss drugs market. Moreover, these drugs are used to maintain a healthy body weight amid growing adoption of a healthy lifestyle, thereby driving the expansion of the market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prescription Weight Loss Pills market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)
Segment by Type
Oral Tablets
Oral Capsules
Injections
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prescription Weight Loss Pills report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices